Neuren and Acadia expand global partnership for trofinetide
Filed with ASX · · 4 pages · English
Neuren Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Neuren Pharmaceuticals
- Neuren completes enrolment in Phelan-McDermid Phase 2 trial
- Neuren opens first site in US for Prader-Willi Phase 2 trial
- Neuren receives US$40m milestone payment
- Q1 2023 quarterly activity and cash flow report
- DAYBUE (trofinetide) launched in US - Neuren earns US$40m
Later from Neuren Pharmaceuticals
- Neuren receives US$100m for expanded DAYBUE agreement
- Q2 2023 quarterly activity and cash flow report
- S&P DJI Announces September 2023 Quarterly Rebalance
- Q3 2023 quarterly activity and cash flow report
- DAYBUE net sales US$66.9 million in Q3 2023
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals